Specific apoCIII proteoform ratios are associated with a healthier cardiometabolic phenotype and lower incidence of type 2 diabetes: a nested case-control study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Apolipoprotein CIII (apoCIII) is a key regulator of triglyceride metabolism and an emerging biomarker of cardiometabolic risk. Although elevated total apoCIII concentrations have been associated with type 2 diabetes (T2D) and cardiovascular disease, individual apoCIII proteoforms may exert distinct metabolic effects. We investigated the prospective associations between apoCIII proteoforms and incident T2D in adults at high cardiometabolic risk, as well as their associations with dietary intake. Methods This nested case-control study included 594 incident T2D cases and 594 controls matched for age, sex, intervention group, body mass index, fasting glucose and triglyceride concentrations. Seven apoCIII proteoforms were measured using mass spectrometry-based immunoassay, and total apoCIII concentrations were measured using an immunoturbidimetric assay. Associations between apoCIII proteoforms and metabolic traits, dietary factors, and incident T2D were evaluated using multivariable-adjusted regression models. Results ApoCIII proteoforms showed heterogeneous associations with metabolic risk and incident T2D. Higher CIII2d/CIII1, CIII2/CIII1, and CIII0f/CIII1 ratios were associated with more favourable lipid and glycaemic profiles and lower odds of incident T2D per 1-SD increase (CIII2d/CIII1 OR = 0.77, 95% CI: 0.61–0.97; CIII2/CIII1 OR = 0.81, 95% CI: 0.69–0.96; CIII0f/CIII1 OR = 0.73, 95% CI: 0.55–0.97). Exploratory analyses identified several nominal associations between dietary intake and apoCIII proteoform ratios; however, none remained statistically significant after FDR correction. Conclusions Higher CIII2d/CIII1, CIII2/CIII1, and CIII0f/CIII1 proteoform ratios were associated with healthier lipid and glucose metabolic profiles and lower odds of incident T2D. These findings support further investigation of apoCIII proteoform profiling as a potential biomarker of incident T2D risk.
Source: Cardiovascular Diabetology
Authors: Helena Banús, Jesús Francisco García-Gavilán, Pere Rehues, Miguel Ángel Martínez-González, Dolores Corella, Montserrat Fitó, J. Alfredo Martínez, Ángel M. Alonso-Gómez, Julia Wärnberg, Jesús Vioque, Dora Romaguera, José López-Miranda, Ramon Estruch, Francisco J. Tinahones, Víctor Urbano-Fernández, Lluís Serra-Majem, Aurora Bueno-Cavanillas, Josep A. Tur, Vicente Martín Sánchez, Xavier Pintó, Miguel Delgado-Rodríguez, Pilar Matía-Martín, Josep Vidal, Clotilde Vázquez, Lidia Daimiel, Emili Ros, Miguel Ruiz-Canela, Josefa Girona, Eva M. Asensio, Albert Goday, Antonio Garcia-Rios, Laura Torres-Collado, Napoleón Pérez-Farinós, Diego Martínez-Urbistondo, Miquel Fiol, Rosa Casas, M. Angeles Castillo-Hermoso, Lucas Tojal-Sierra, Víctor José Simón-Frapolli, Nuria Goñi, Carolina Ortega-Azorín, Olga Castañer, Jose David Torres-Peña, Concepción Barceló, Estefania Toledo, Montse Guardiola, Helmut Schröder, Jordi Salas-Salvadó, Josep Ribalta
Institutions: Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Institut de Recerca Biomèdica Catalunya Sud, Universitat Rovira i Virgili, Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Centro de Investigación Biomédica en Red, Karolinska University Hospital, Karolinska Institutet, Harvard University, Navarre Institute of Health Research, Universidad de Navarra, Universitat de València, Hospital Del Mar, Municipal Institute for Medical Research, Hospital del Mar Research Institute, Madrid Institute for Advanced Studies, Comunidad de Madrid, University of the Basque Country, Hospital Universitario Araba, Osakidetza, Andalusian Centre for Nanomedicine and Biotechnology, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Universitat de Miguel Hernández d'Elx, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Health Research Institute of the Balearic Islands, Hospital Universitario Son Espases, Instituto Maimónides de Investigación Biomédica de Córdoba, Hospital Universitario Reina Sofía, University of Córdoba, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Universidad de Sevilla, Universidad de Las Palmas de Gran Canaria, Universidad de Granada, Universitat de les Illes Balears, Universidad de León, Bellvitge University Hospital, Universidad de Jaén, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Universidad San Pablo CEU, IMDEA Food, Hospital Clínic de Barcelona, Universitat Pompeu Fabra, Clinica Universidad de Navarra, Hospital Clínico Universitario Virgen de la Victoria, Servicio Navarro de Salud
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,290
OpenAlex ID: W7226003503
